BioInvest In The News

Dash of Insight (11-16-14)
Biotech Watchlist Update (11-6-14)
MoneyShow Biotech Bets (11-3-14)
Five Prime: A Prime Play on Proteins (9-22-14)
U~T San Diego Isis Pharmaceuticals (9-3-14)
Dick Davis Investment Digest (7-23-14)
Company Updates
Isis Update (12-9-2014)

Isis Update (12-9-2014)

Special ASH Update for ISIS ISIS Factor XI Data Published in NEJM, 2nd Time in One Week:  Isis has been an unexpected star at ASH as they have released the final Phase II data for ISIS-FXI at ASH and were also published in the New England Medical Journal.  The data showed a significant reduction (seven-fold [...]

Pharmacyclics Update (9-10-14)

Pharmacyclics Update (9-10-14)

Special Update – PCYC Scores VA Contract, PCYC Shares Still Undervalued – In breaking news, PCYC has been awarded a large Veterans Affairs (VA) contract for Imbruvica.   Details – VA – A Large Buying Group: The following information was posted today (dated September 4, 2014)   Solicitation Number: VA797P14R0033 Contract Award Date: September 4, [...]

Pharmacyclics Update (7-23-14)

Pharmacyclics Update (7-23-14)

SPECIAL UPDATE – PCYC – GILD Severely Restrictive Zydelig Label Underscores Imbruvica’s Superior Profile – Reiterate BUY – Gilead received approval midday for Zydelig (idelalisib) for three blood cancers – refractory CLL, indolent FL and SLL – some what ahead of the August/September PDUFA dates.  While the approvals were widely expected, the strict BLACK BOX [...]